Before Exelexis’ Cabometyx can pass muster with the FDA in its hopeful neuroendocrine tumors indication next April, it will have to first face the agency’s Oncologic Drugs Advisory Committee ( | The ...
Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be ...
Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...
Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer antidepressant, reduced bouts of cataplexy and other narcolepsy symptoms in ...
On a routine basis in recent years, headlines about layoffs in the biopharma industry have surfaced as companies large and ...
Hovione, a Portuguese CDMO that specializes in spray drying, completed multiyear expansion projects at manufacturing ...
More than three years into a lawsuit accusing competitor Natera of disparaging its cancer blood test, Guardant Health has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback